What is the current valuation of the Small Molecule Drug Discovery Market?

As of 2024, the market was valued at 74.08 USD Billion. Read More

What is the projected market size for the market by 2035?

The market is projected to reach 191.2 USD Billion by 2035. Read More

What is the expected CAGR for the Small Molecule Drug Discovery Market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period 2025 - 2035 is 9.0%. Read More

Which therapeutic area is expected to have the highest market valuation in 2035?

Oncology is anticipated to reach a market valuation of 50.0 USD Billion by 2035. Read More

What are the projected market values for cardiovascular diseases in 2035?

The market for cardiovascular diseases is projected to reach 35.0 USD Billion by 2035. Read More

Which type of target is expected to dominate the market by 2035?

Proteins are expected to dominate the market, reaching a valuation of 54.56 USD Billion by 2035. Read More

What is the expected market size for computational drug design by 2035?

Computational drug design is projected to reach 77.2 USD Billion by 2035. Read More

How do pharmaceutical companies compare to contract research organizations in market size by 2035?

Pharmaceutical companies are expected to reach 80.0 USD Billion, surpassing contract research organizations at 60.0 USD Billion by 2035. Read More

Which key players are leading the Small Molecule Drug Discovery Market?

Key players include Pfizer, Novartis, Merck & Co., and Bristol-Myers Squibb, among others. Read More

What is the expected market valuation for metabolic disorders by 2035?

The market for metabolic disorders is projected to reach 51.2 USD Billion by 2035. Read More

Small Molecule Drug Discovery Market

ID: MRFR/HC/20284-HCR

128 Pages

Nidhi Mandole

Last Updated: May 15, 2026

Small Molecule Drug Discovery Market Research Report: Size, Share, Trend Analysis By Therapeutic Area (Oncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Metabolic Disorders), By Types of Target (Enzymes, Receptors, Proteins, Nucleic Acids), By Technology (High-Throughput Screening, Structure-Based Drug Design, Fragment-Based Drug Design, Computational Drug Design), By End Use (Pharmaceutical Companies, Contract Research Organizations, Academic Institutions) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Small Molecule Drug Discovery Market Infographic

Summary Table of Contents Segmentation Methodology Download PDF

Certified Researchers

Customize Report

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Therapeutic Area (USD Billion) | |
  1. 4.1.1 Oncology | |
  2. 4.1.2 Cardiovascular Diseases | |
  3. 4.1.3 Neurological Disorders | |
  4. 4.1.4 Infectious Diseases | |
  5. 4.1.5 Metabolic Disorders |
2. 4.2 Healthcare, BY Type of Target (USD Billion) | |
  1. 4.2.1 Enzymes | |
  2. 4.2.2 Receptors | |
  3. 4.2.3 Proteins | |
  4. 4.2.4 Nucleic Acids |
3. 4.3 Healthcare, BY Technology (USD Billion) | |
  1. 4.3.1 High-Throughput Screening | |
  2. 4.3.2 Structure-Based Drug Design | |
  3. 4.3.3 Fragment-Based Drug Design | |
  4. 4.3.4 Computational Drug Design |
4. 4.4 Healthcare, BY End Use (USD Billion) | |
  1. 4.4.1 Pharmaceutical Companies | |
  2. 4.4.2 Contract Research Organizations | |
  3. 4.4.3 Academic Institutions |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Pfizer (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Novartis (CH) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Merck & Co. (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Bristol-Myers Squibb (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 AstraZeneca (GB) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Johnson & Johnson (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Gilead Sciences (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Eli Lilly and Company (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Sanofi (FR) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY THERAPEUTIC AREA |
7. 6.4 US MARKET ANALYSIS BY TYPE OF TARGET |
8. 6.5 US MARKET ANALYSIS BY TECHNOLOGY |
9. 6.6 US MARKET ANALYSIS BY END USE |
10. 6.7 CANADA MARKET ANALYSIS BY THERAPEUTIC AREA |
11. 6.8 CANADA MARKET ANALYSIS BY TYPE OF TARGET |
12. 6.9 CANADA MARKET ANALYSIS BY TECHNOLOGY |
13. 6.10 CANADA MARKET ANALYSIS BY END USE |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY THERAPEUTIC AREA |
16. 6.13 GERMANY MARKET ANALYSIS BY TYPE OF TARGET |
17. 6.14 GERMANY MARKET ANALYSIS BY TECHNOLOGY |
18. 6.15 GERMANY MARKET ANALYSIS BY END USE |
19. 6.16 UK MARKET ANALYSIS BY THERAPEUTIC AREA |
20. 6.17 UK MARKET ANALYSIS BY TYPE OF TARGET |
21. 6.18 UK MARKET ANALYSIS BY TECHNOLOGY |
22. 6.19 UK MARKET ANALYSIS BY END USE |
23. 6.20 FRANCE MARKET ANALYSIS BY THERAPEUTIC AREA |
24. 6.21 FRANCE MARKET ANALYSIS BY TYPE OF TARGET |
25. 6.22 FRANCE MARKET ANALYSIS BY TECHNOLOGY |
26. 6.23 FRANCE MARKET ANALYSIS BY END USE |
27. 6.24 RUSSIA MARKET ANALYSIS BY THERAPEUTIC AREA |
28. 6.25 RUSSIA MARKET ANALYSIS BY TYPE OF TARGET |
29. 6.26 RUSSIA MARKET ANALYSIS BY TECHNOLOGY |
30. 6.27 RUSSIA MARKET ANALYSIS BY END USE |
31. 6.28 ITALY MARKET ANALYSIS BY THERAPEUTIC AREA |
32. 6.29 ITALY MARKET ANALYSIS BY TYPE OF TARGET |
33. 6.30 ITALY MARKET ANALYSIS BY TECHNOLOGY |
34. 6.31 ITALY MARKET ANALYSIS BY END USE |
35. 6.32 SPAIN MARKET ANALYSIS BY THERAPEUTIC AREA |
36. 6.33 SPAIN MARKET ANALYSIS BY TYPE OF TARGET |
37. 6.34 SPAIN MARKET ANALYSIS BY TECHNOLOGY |
38. 6.35 SPAIN MARKET ANALYSIS BY END USE |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC AREA |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY TYPE OF TARGET |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USE |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA |
45. 6.42 CHINA MARKET ANALYSIS BY TYPE OF TARGET |
46. 6.43 CHINA MARKET ANALYSIS BY TECHNOLOGY |
47. 6.44 CHINA MARKET ANALYSIS BY END USE |
48. 6.45 INDIA MARKET ANALYSIS BY THERAPEUTIC AREA |
49. 6.46 INDIA MARKET ANALYSIS BY TYPE OF TARGET |
50. 6.47 INDIA MARKET ANALYSIS BY TECHNOLOGY |
51. 6.48 INDIA MARKET ANALYSIS BY END USE |
52. 6.49 JAPAN MARKET ANALYSIS BY THERAPEUTIC AREA |
53. 6.50 JAPAN MARKET ANALYSIS BY TYPE OF TARGET |
54. 6.51 JAPAN MARKET ANALYSIS BY TECHNOLOGY |
55. 6.52 JAPAN MARKET ANALYSIS BY END USE |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC AREA |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY TYPE OF TARGET |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USE |
60. 6.57 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC AREA |
61. 6.58 MALAYSIA MARKET ANALYSIS BY TYPE OF TARGET |
62. 6.59 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY |
63. 6.60 MALAYSIA MARKET ANALYSIS BY END USE |
64. 6.61 THAILAND MARKET ANALYSIS BY THERAPEUTIC AREA |
65. 6.62 THAILAND MARKET ANALYSIS BY TYPE OF TARGET |
66. 6.63 THAILAND MARKET ANALYSIS BY TECHNOLOGY |
67. 6.64 THAILAND MARKET ANALYSIS BY END USE |
68. 6.65 INDONESIA MARKET ANALYSIS BY THERAPEUTIC AREA |
69. 6.66 INDONESIA MARKET ANALYSIS BY TYPE OF TARGET |
70. 6.67 INDONESIA MARKET ANALYSIS BY TECHNOLOGY |
71. 6.68 INDONESIA MARKET ANALYSIS BY END USE |
72. 6.69 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC AREA |
73. 6.70 REST OF APAC MARKET ANALYSIS BY TYPE OF TARGET |
74. 6.71 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY |
75. 6.72 REST OF APAC MARKET ANALYSIS BY END USE |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY THERAPEUTIC AREA |
78. 6.75 BRAZIL MARKET ANALYSIS BY TYPE OF TARGET |
79. 6.76 BRAZIL MARKET ANALYSIS BY TECHNOLOGY |
80. 6.77 BRAZIL MARKET ANALYSIS BY END USE |
81. 6.78 MEXICO MARKET ANALYSIS BY THERAPEUTIC AREA |
82. 6.79 MEXICO MARKET ANALYSIS BY TYPE OF TARGET |
83. 6.80 MEXICO MARKET ANALYSIS BY TECHNOLOGY |
84. 6.81 MEXICO MARKET ANALYSIS BY END USE |
85. 6.82 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC AREA |
86. 6.83 ARGENTINA MARKET ANALYSIS BY TYPE OF TARGET |
87. 6.84 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY |
88. 6.85 ARGENTINA MARKET ANALYSIS BY END USE |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC AREA |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF TARGET |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC AREA |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF TARGET |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USE |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC AREA |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF TARGET |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USE |
102. 6.99 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC AREA |
103. 6.100 REST OF MEA MARKET ANALYSIS BY TYPE OF TARGET |
104. 6.101 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY |
105. 6.102 REST OF MEA MARKET ANALYSIS BY END USE |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY TYPE OF TARGET, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY TYPE OF TARGET, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY END USE, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY END USE, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY END USE, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY END USE, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY END USE, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY END USE, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY END USE, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY END USE, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY END USE, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY END USE, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY END USE, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY END USE, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY END USE, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY END USE, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY END USE, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY END USE, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY END USE, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY END USE, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY END USE, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY END USE, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY END USE, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY END USE, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY END USE, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY END USE, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY END USE, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY END USE, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY END USE, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY END USE, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY END USE, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY TYPE OF TARGET, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY END USE, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Therapeutic Area (USD Billion, 2025-2035)

Oncology
Cardiovascular Diseases
Neurological Disorders
Infectious Diseases
Metabolic Disorders

Healthcare By Type of Target (USD Billion, 2025-2035)

Enzymes
Receptors
Proteins
Nucleic Acids

Healthcare By Technology (USD Billion, 2025-2035)

High-Throughput Screening
Structure-Based Drug Design
Fragment-Based Drug Design
Computational Drug Design

Healthcare By End Use (USD Billion, 2025-2035)

Pharmaceutical Companies
Contract Research Organizations
Academic Institutions

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”